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Abstract
Cystinosis is a rare disease caused by homozygous mutations of the CTNS gene, encoding a cystine efflux channel in the
lysosomal membrane. In Ctns knockout mice, the pathologic intralysosomal accumulation of cystine that drives progressive
organ damage can be reversed by infusion of wildtype bone marrow-derived stem cells, but the mechanism involved is
unclear since the exogeneous stem cells are rarely integrated into renal tubules. Here we show that human mesenchymal
stem cells, from amniotic fluid or bone marrow, reduce pathologic cystine accumulation in co-cultured CTNS mutant
fibroblasts or proximal tubular cells from cystinosis patients. This paracrine effect is associated with release into the culture
medium of stem cell microvesicles (100–400 nm diameter) containing wildtype cystinosin protein and CTNS mRNA. Isolated
stem cell microvesicles reduce target cell cystine accumulation in a dose-dependent, Annexin V-sensitive manner.
Microvesicles from stem cells expressing CTNSRed transfer tagged CTNS protein to the lysosome/endosome compartment of
cystinotic fibroblasts. Our observations suggest that exogenous stem cells may reprogram the biology of mutant tissues by
direct microvesicle transfer of membrane-associated wildtype molecules.
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Introduction
Cystinosis is a rare disorder caused by homozygous mutations of
the CTNS gene on the short arm of chromosome 17q, encoding a
ubiquitous cystine-selective transport channel in the lysosomal
membrane [1]. Loss of this transporter prevents cystine efflux from
the lysosome, causing massive accumulation of intralysosomal
cystine in tissues throughout the body [2,3] and eventual apoptotic
cell death [4]. Affected children may appear fairly well until the
age of 4–6 months, when progressive dysfunction and atrophy of
the proximal tubule cause renal Fanconi syndrome and failure to
thrive [5]; by 10–12 years of age, dialysis or kidney transplantation
is required to treat end-stage renal disease. Although the renal
allograft is spared, lifespan is diminished by the inexorable
dysfunction of other organs, including the thyroid gland, lungs,
muscles, retina and brain [6].
In the late 1980’s, it was discovered that the pathologic
accumulation of cystine could be substantially reduced by
cysteamine therapy. This drug attacks the internal disulfide bond
of cystine to form mixed disulfides that are able to efflux from the
lysosome via alternative transport channels [2,7,8,9]. With the
introduction of oral cysteamine therapy during infancy, the
natural history of cystinosis was modified so as to delay the
deterioration of the kidneys and other organs [10]. A cysteamine
dose of 1.3 g/m2/day typically reduces leukocyte cystine levels to
about 15% of baseline. However, the odour and gastric side-effects
of oral cysteamine make adherence extremely difficult. Further-
more, even well-treated patients eventually require kidney
transplantation and develop profound distal myopathy, cerebral
atrophy and other complications as young adults [11]. Survival
past the age of 30 years is uncharacteristic.
It was with great interest, therefore, that the medical community
learned in 2009 of successful bone marrow stem cell therapy of
Ctns 2/2 knockout mice [12]. Syres et al infused allogeneic
wildtype bone marrow stem cells into Ctns 2/2 knockout mice
after partial ablation of the bone marrow. The exogenous stem
cells were progressively retained by cystinotic organs, resulting in
90% decrease in tissue cystine levels and, in the case of the kidney,
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leading to normalization of organ dysfunction [12]. However, two
aspects of these observations are puzzling. Firstly, the reduction in
tissue cystine levels cannot be explained by a dilutional effect
produced by the arrival of wildtype stem cells; the investigators
estimated that mutant organ Ctns transcript level rose to only 10%
of normal [12,13]. Furthermore, infusion of GFP-tagged stem cells
showed that the vast majority of exogenous cells took up a stromal
position adjacent to the intrinsic nephrons and were only rarely
integrated into the epithelia wall of renal tubules [12,13]. Thus,
the profound decrease in whole-organ cystine level cannot be
attributed to either stem cell transdifferentiation or fusion with
resident mutant cells.
Stem cells are known to exert a number of useful paracrine
effects, including the release of soluble factors that suppress
inflammation or stimulate proliferation of endogenous cells
following acute organ injury [14]. However, neither mechanism
can be expected to correct the defective lysosomal transport
channel in cystinosis. Recently, Al-Nedawi et al reported that
cancer stem cells shed microvesicles from the cell surface and that
endocytotic uptake of the microvesicles transfers epidermal growth
factor receptors to nearby endothelia; this induces proliferation of
the normal endothelial cells, by rendering them responsive to local
transforming growth factor-alpha [15,16,17]. We hypothesized
that, in similar fashion, stem cell microvesicles could transfer
wildtype cystinosin to membrane compartments of adjacent
mutant cell targets. In this study, we use an in vitro co-culture
model to demonstrate that human stem cells reverse cystine
accumulation in cystinotic cells in paracrine fashion. We
demonstrate that mesenchymal stem cells shed microvesicles
containing wildtype cystinosin protein and CTNS mRNA into
the culture medium and that uptake of isolated microvesicles
transfers CTNS protein to the lysosomal compartment of
cystinotic fibroblasts and reverses pathologic cystine accumulation.
Materials and Methods
Ethic Statement
The cells used in this study were obtained from the Cell
Repository from the Montreal Children’s Hospital with ethical
approval from the Montreal Children’s Hospital Research Ethics
Board. For cell lines previously published, ethical approval was
obtained and stated in the corresponding reference.
Vectors, RT/PCR and genotyping
CTNSRed was previously described [18]. pEGFP-C3 plasmid
was purchased from Clontech (Clonetech, #6082-1). A lentiviral
vector (LV) encoding the CTNS sequence linked to a triple repeat
of the flag tag was constructed as follows. The CTNS cDNA
sequence was amplified from the pCDNA3-CTNS T260I plasmid
and inserted into a lentiviral transfer construct (pCHMWS-3F-
MCS-ires-BsdR). The resulting construct was sequence verified.
This transfer construct encodes the 3F-CTNS under the control of
the ubiquitous CMV promoter and also includes a blasticidine
resistance gene to select the transduced cells. A second generation
lentiviral vector was produced as previously described [19].
Total RNA was isolated with RNeasy kit (Qiagen). Purity and
concentration of RNA were determined with a NanoDrop ND-
1000 (NanoDrop Technologies, Inc). Transcripts were amplified
(35 cycles) using: CTNS(f) 59-gcagtcacgctggtcaagta-39, and
CTNS(r1) 59-caggaaagtggccttcagag-39 or CTNS(r2) 59-cgaagacgatg-
gagaagacc-39; GAPDH(f) 59-gagtcaacggatttggtcgt-39, GAPDH(r) 59-
gatctcgctcctggaagatg -39. Genotyping for CTNS mutation was
performed with primers LDM1 flanking the common 57 Kb
deletion or CTNS Exon 4 [20].
Cell culture
Normal human amniotic mesenchymal stem cells (amMSC,
passage 5–20) and adult bone marrow cells (bmMSC, passage 3–8)
[21] were maintained in DMEM (Invitrogen) supplemented with
15–20% FBS (Wisent) and 1% Penicillin/Streptomycin (Invitro-
gen). Skin fibroblasts (Fib) from cystinotic patients and controls
were maintained in DMEM with 10% FBS. Conditionally
immortalized mutant proximal tubular epithelial cells (ciPTEC)
obtained with ethics approval from the urine of a cystinosis patient
bearing the common homozygous 57 kb deletion were previously
characterized [22].
Characterization of MSCs
One million cells were incubated for 30 minutes at +4uC with
the following monoclonal antibodies: phycoerythrin-labeled HLA-
DR (clone LN3) from eBioscience, allophycocyanin-labeled CD34
(clone 581), phycoerythrin-labeled CD44 (clone G44-26), phyco-
erythrin-labeled CD31 (clone WM59), phycoerythrin-labeled
CD105 (clone 266), phycoerythrin-labeled CD45 (clone HI30),
fluorescein isothiocyanate-labeled CD90 (clone 5E10), phycoery-
thrin-labeled CD73 (clone AD2) from BD Biosciences (BD
Biosciences Pharmingen, Mississauga, ON). Cells were analyzed
with CellQuest Pro software on a FACSCalibur flow cytometer
(BD Biosciences), using antibody isotype controls. In order to test
for osteogenic differentiation of MSCs the cells were exposed to
complete media supplemented with b-glycerol phosphate
(10 mmol/l; Sigma-Aldrich), ascorbic acid 2-phosphate
(50 mmol/l; Sigma-Aldrich), and dexamethasone (1028 mol/l;
Sigma-Aldrich) for 4 weeks and then stained with 1% Alizarin
Red S (Sigma-Aldrich). In order to test for adipogenic differen-
tiation of MSCs, cells were exposed to complete media supple-
mented with insulin (5 mg/ml), dexamethasone (1 mmol/l; Sigma-
Aldrich), 3-isobutyl-methylxanthine (0.5 mmol/l; Sigma-Aldrich),
and indomethacin (60 mmol/l; Sigma-Aldrich) for 14 days, and
then stained with Oil Red O (Sigma-Aldrich).
Microvesicles (MV)
Microvesicles were isolated from conditioned culture medium as
described by Al-Nedawi [16]. Briefly, the culture medium is
subjected to centrifugation at 3006g for 5 min at 4uC to remove
debris and then ultracentrifuged at 100,000 g (Beckman Coulter
Optima L-80 ultracentrifuge) for 2 hrs at 4uC, and resuspended in
PBS after two washes with PBS each followed by ultracentrifu-
gation at 100,000 g for 1 hr at 4uC. MV were analyzed with
NanoSight LM20 (NanoSight, Amesbury, United Kingdom) using
NTA2.1 software. MV protein was quantified (BCA protein assay
kit, Calbiochem). Various amounts of MV were incubated for
24 hrs with target cells. Cell pellets were washed and assayed for
protein and cystine content.
Cell cystine assay
For cystine assays, cells were grown in cystine-free culture
medium for 24 hours. Cystine was measured by HPLC with
homocysteine as an internal control [23]. Results are expressed as
nmol half-cystine per mg cell protein.
Microscopy
CTNSRed tagged cells and microvesicles were inspected with a
Zeiss Axiophot inverted microscope and analyzed using Axiovision
Rel v 4.7.1 software. Microvesicles isolated from non- transfected
amMSC were used as a negative control for imaging. Confocal
fluorescent live cell microscopy was performed using a Quorum
Wave FX Spinning Disc confocal microscope (Quorum Technol-
Stem Cell Microvesicles Rescue Cystinotic Cells
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ogies Inc.) equipped with a 1.4 NA 636oil lens, Leica DMI6000 B
microscope, Yokowaya CSU-10 spinning disc confocal head and a
Hamamatsu ImagEM (EM-CCD) camera. Images were acquired
using 0.2 micron optical sectioning and analysed using the
Improvision Volocity software. Images were registration corrected
and deconvolved. Briefly, cells were grown on Lab-tek II
chambered coverglass slides (Nalge Nunc International). In some
experiments, MV bearing CTNSRed were added to mutant cell
monolayers 4 hours before confocal microscopy. LysoTracker
probe (50 nM, Invitrogen) was added 10 min before image
capture.
Statistical analysis
Statistical analysis were performed using paired, two tailed
Student’s t-test. Data bars and error bars indicate mean 6
standard deviation.
Results
amMSC cells reduce cystine accumulation in co-cultured
cystinotic fibroblasts or cystinotic proximal tubular cells
To study the paracrine effects of wildtype stem cells on nearby
adjacent mutant cell targets, we first isolated mesenchymal stem
cells from bone marrow of healthy adults (bmMSC) (Figure 1a)
and normal human amniotic fluid (18 weeks gestation) (amMSC)
(Figure 1b). Each cell line was shown to express typical
mesenchymal stem cell markers (CD44, CD73, CD90 and
CD105), but not endothelial (CD31), hematopoietic (CD34,
CD45) or MHC (HLA-DR) markers. Both mesenchymal stem
cell lines could be induced to differentiate toward osteogenic and
adipocyte fates (Figures 1a and 1b, right panels).
We then co-cultured amniotic mesenchymal stem cells
(amMSC) with various proportions of mutant fibroblasts from a
cystinosis patient with homozygous deletion of the CTNS gene
(Figure 1c, left panel) containing high intracellular levels of
cystine (Figure 1c, right panel). After 4 days in co-culture, we
measured the cystine content of the mixed cell population and
calculated the cystine attributable to the subset of mutant target
cells. As seen in Figure 2a, mutant cell cystine was significantly
reduced in proportion to the number of wildtype amMSC in the
co-culture, demonstrating a paracrine effect of the stem cells on
their cystinotic neighbors.
In a second set of experiments, we measured cystine content in
GFP-tagged mutant conditionally-immortalized proximal tubular
target cells (ciPTEC(2/2)GFP) after co-culture with a variety of
donor cells. The target ciPTEC(2/2)GFP cells were from a
cystinosis patient bearing the common homozygous 57 kb deletion
of the CTNS gene [22]. After 4 days of co-culture, the GFP-tagged
mutant target cells were isolated by fluorescence-activated cell
sorting (FACS), following forward and then side scatter width/
height gating to assure isolation of singlet cells only. The cells were
then analyzed for cystine content. As seen in Figure 2b, co-
culture with amMSC donors dramatically reduces cystine content
in the ciPTEC(2/2)GFP targets compared to baseline. In another
set of experiments, ciPTEC(2/2)GFP cell cystine was unaffected
by co-culture with untagged mutant proximal tubular ciPTEC(2/
2) donor cells; on the other hand, co-culture of ciPTEC(2/2)GFP
with genetically corrected (transfected with wildtype CTNS)
ciPTEC(2/2) cells again showed significant reduction of cystine
content (Figure 2b). Taken together, these experiments identify a
paracrine effect of wildtype donor cells on cystine content in
nearby CTNS mutant target cells. The effect requires a wildtype
CTNS gene in the donor but is not restricted to a unique donor cell
type. Neither is the effect restricted to a specific cystinotic cell
target.
MSC microvesicles reduce pathologic accumulation of
cystine in mutant fibroblasts from cystinosis patients
Al-Nedawi et al suggested that an important characteristic of
stem cells is that they shed plasma membrane-derived micropar-
ticles into the local environment and these are taken up by
neighboring cells [17]. We reasoned that this mechanism might
account for the paracrine effects of MSC on cystinotic cells. To
address this hypothesis, monolayers of FACS-purified bmMSC
were cultured for 48 hours and microparticles in the conditioned
medium were isolated by ultracentrifugation [16]. Nanosight
analysis of the suspended particles showed that over 95% had a
diameter typical of microvesicles (100–400 nm) (Figure 3a).
Microvesicles shed by amMSC into culture medium with 0.5%
BSA (about 2500 microvesicles/cell/day) showed a similar profile
(Figure 3c).
To ascertain whether MSC microvesicles can reduce cystine
content of CTNS mutant target cells, we isolated microvesicles
from bmMSC or amMSC and transferred them to separate
monolayer cultures of CTNS mutant fibroblasts (2/2) for
24 hours (1–2 mg microvesicles/mg fibroblast protein). The cells
were then harvested and assayed for cystine content as above. As
seen in Figure 3b, bmMSC microvesicles reduced mutant cell
cystine level in a dose-dependent fashion. At the highest
microvesicle dose studied, cell cystine was reduced even more
than exposure to 1 mM cysteamine for 24 hours. A similar effect
was noted with microvesicles isolated from amMSC (Figure 3d).
Pre-treatment of microvesicles with annexin V (2 ug/150 ug
microvesicle protein) completely blocked their ability to reduce
mutant cell cystine accumulation, indicating that phosphatidylser-
ine-dependent uptake of the microvesicles by target cells is
necessary for the effect [24] (Figure 3d).
Stem cell microvesicles transfer wildtype cystinosin
protein to mutant target cells
To test the possibility that microvesicles mediate direct CTNS
protein transfer between donor and recipient cells, we stably
transfected amMSC with CTNSRed (Figure 4a). We inspected
red fluorescence in an aliquot of microvesicles obtained from
culture media from the stably transfected amMSC with CTNSRed.
The Red-tagged CTNS protein was evident in microvesicles shed
into the conditioned medium (Figure 4b). We then co-cultured
amMSC/CTNSRed with an equal number of CTNS(2/2)GFP
fibroblast targets; there was no evidence of fusion between donor
and target cells. As seen in Figure 4c, CTNSRed particles are
visible in a single confocal plane within a cluster of amMSC
(shown in the bright field microscopy image, Figure 4c inset) and
within CTNS(2/2)GFP fibroblasts, indicating transfer of the
tagged protein from amMSC to the target cell.
We also tracked the fate of CTNSRed vesicles (Figure 4d inset)
applied directly to cultured CTNS(2/2) fibroblasts stained with a
green-fluorescent endosomal/lysosomal dye. As seen by confocal
microscopy (Figure 4d), CTNSRed-tagged particles were again
observed within the target cells. Furthermore, we were able to
identify CTNSRed-tagged particles co-localizing with green fluo-
rescent-tagged intracellular structures, documenting transfer to the
acidic intracellular endosomal/lysosomal compartment of mutant
target cells.
Stem Cell Microvesicles Rescue Cystinotic Cells
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Figure 1. Characterization of mesenchymal stem cells and CTNS(2/2) mutant target cells. (a) FACS analysis (left) of bmMSC surface
markers (blue) and isotype controls (red) and bmMSC differentiation from baseline (upper right) to Alizarin Red S-stained calcium-containing
osteogenic (middle right) and Oil-Red O-stained adipocyte (bottom right) phenotypes. (b) same FACS and differentiation analysis of amMSC cells. (c)
Stem Cell Microvesicles Rescue Cystinotic Cells
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Stem cell microvesicles also transfer CTNS mRNA to
CTNS(2/2) fibroblasts
Other investigators have shown that microvesicles contain mRNA
and miRNA as well as protein [25]. We were able to detect wildtype
CTNS transcripts by RT/PCR in microvesicles isolated from
amMSC (Figure 5a). We co-cultured CTNS(2/2)GFP fibroblasts
with either amMSC or unlabelled CTNS(2/2) fibroblast donors for
48 hours and then separated the CTNS(2/2)GFP fibroblasts by
FACS. As seen in Figure 5b, wildtype CTNS transcripts were
detectable by RT/PCR in the mutant recipient target cell co-
cultured with amMSC, but not with the mutant fibroblast donors.
Discussion
Long regarded as inactive cellular debris, microvesicles shed
from the surface of viable cells are increasingly recognized as
important vehicles for the transfer of complex biologic information
between neighboring cells. Microvesicles arise either through
vesiculation of the plasma membrane to generate 100–500 nm
diameter particles exposing phosphatidyl serine residues shifted to
the outer leaflet (ectosomes) or through redirection of endosomal
structures to multivesicular bodies that disgorge their 40—80 nm
diameter particles (exosomes) into the extracellular environment
[24]. Unlike other intercellular communication mechanisms, such
as release of neurotransmitters or soluble growth factors,
endocytotic uptake of microvesicles allows transfer of membrane-
associated protein complexes as well as certain cytoplasmic
constituents such as mRNA and miRNA [24]. Proteomic analysis
suggests that microvesicles carry about 500 hundred protein
cargoes from the donor cell which could re-program the
membrane biology of the recipient [26].
While many cells shed microvesicles, flux from the surface of
stem cells and cancer cells is thought to be especially high and may
exert important influence on the stem cell niche or on tumour
invasiveness. Here, we show that mesenchymal stem cells shed
microvesicles containing wildtype cystinosin protein and mRNA.
Uptake of these microvesicles by mutant CTNS(2/2) fibroblasts
or proximal tubule cells delivers CTNS to the endosomal/
lysosomal compartment and reduces the pathologic accumulation
of cystine. This provides a plausible mechanism to explain the
clinical effects of bone marrow stem cell infusion on Ctns knockout
mice [12,13]. In our studies, mutant fibroblast cystine accumula-
tion was substantially reduced within four days when co-cultured
(4:1) with a relatively small proportion of wildtype stem cells. We
hypothesize that continuous microvesicle transfer between infil-
trating stem cells and adjacent mutant epithelial cells reasonably
accounts for the therapeutic effects accrued over several months in
Syres’ experiments.
In the study by Syres et al, optimal clinical effect was obtained by
infusion of 20 million wildtype hematopoietic stem cells (HSC) into
Ctns knockout mice [12]. This resulted in excellent engraftment,
increasing uptake of HSC in cystinotic tissues and striking (80%)
reduction in tissue cystine content by four months. Although GFP-
tagged HSC were occasionally incorporated into tubules, the vast
majority of HSC took up an interstitial position in cystinotic
organs. Similar studies were attempted with bone marrow-derived
schematic diagram depicting the common 57 Kb deletion removing the 59 portion of the CTNS gene and PCR-proven genotype of control and
mutant fibroblasts from a cystinosis patient. Intracellular cystine content of control and homozygous CTNS mutant fibroblasts is shown on the right
bar-graph.
doi:10.1371/journal.pone.0042840.g001
Figure 2. Effect of co-culture with CTNS-expressing cells on
cystine content of mutant CTNS cells. (a) Cystine content of
CTNS(2/2) fibroblasts co-cultured with increasing amounts of wildtype
amMSC. (b) Cystine content of GFP-tagged CTNS(2/2) ciPTEC isolated
by FACS after co-culture with unlabelled wildtype amMSC, mutant
ciPTEC or CTNS-corrected ciPTEC as donors. Statistical significance is
indicated by the corresponding p-value.
doi:10.1371/journal.pone.0042840.g002
Stem Cell Microvesicles Rescue Cystinotic Cells
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mesenchymal stem cells (MSC), but technical issues restricted the
infusion of MSC to only 2 million cells per mouse and MSC
retention in cystinotic tissues diminished with time, making direct
comparisons difficult. Nevertheless, initial engraftment of MSC
was excellent and, at four months, tissue cystine was significantly
reduced (50%) and serum creatinine was similar to that of the
HSC-infused group [12]. Other groups have shown that
exogenous MSC exert important paracrine effects in murine
models of acute kidney injury, particularly when the cells are
derived from amniotic fluid rather than adult bone marrow [27].
In our studies, paracrine reduction of cystine accumulation in
CTNS mutant targets was seen with amniotic fluid MSC, adult
bone marrow MSC and with genetically corrected, immortalized
proximal tubular cells from a cystinosis patient. Although
microvesicle shedding has not been examined in HSC or
immortalized epithelial cells, the phenomenon is consistently seen
in a wide range of stem and cancer cells [24]. It seems likely,
therefore, that the paracrine effects of both HSC and MSC on
cystine content of Ctns(2/2) mouse tissues noted by Syres et al
could be explained by microvesicle shedding.
Our studies show that the majority of microparticles shed by
amMSC or bmMSC monolayers into culture medium containing
0.5% BSA are between 100–400 nm in diameter, characteristic of
microvesicles (ectosomes). Unlike exosomes (,100 nm diameter)
which arise during endosomal recycling within the cell, microves-
icles arise through regulated outward blebbing of lipid raft-
associated areas of the plasma membrane [24]. Since the blebbing
process characteristically exposes phosphatidylserine at the outer
surface, annexin V binds to microvesicles and blocks cargo transfer
to adjacent cells [24]. We found that pre-treatment of amMSC
microvesicles with annexin V completely abrogated their effect on
cystine accumulation in mutant fibroblasts. This indicates that the
rescue effect requires a membrane fusion event between micro-
vesicles (ectosomes) and the target cell membrane rather than
secretion of a soluble signalling molecule or an effect of exosomes.
Bruno et al have shown that MSC infused into mice with
glycerol-induced renal injury ameliorate tissue damage by
suppressing apoptosis and enhancing proliferation of endogenous
cells [28]. In the setting of cystinosis, however, a similar effect on
survival of mutant cells cannot explain the observed reduction in
tissue cystine content. Whereas improved survival or proliferation
of endogenous cells might sustain tubular integrity and function,
the surviving mutant cells would nevertheless exhibit high levels of
intralysosomal cystine. In the study by Bruno, it was also shown
that infusion of isolated microvesicles could mimic the effect of
MSC on acute tissue injury. However, the duration of this effect is
likely to be short-lived and unsustainable as a repeated therapy for
a congenital disease. This is in contrast to successful stem cell
engraftment, where cystinotic cells would be exposed to contin-
uous release of microvesicles containing wildtype cystinosin.
Figure 3. Analysis of stem cell microvesicles and their effects on cystine content of CTNS(2/2) mutant fibroblasts. (a) diameter of
bmMSC microparticles released into conditioned medium. (b) effect of increasing amounts of bmMSC microvesicles on cystine in mutant fibroblasts
after 24 hour incubation, compared to the effect of 1 mM cysteamine. (c) diameter of amMSC microparticles released into conditioned medium. (d)
effect of increasing amounts of amMSC microvesicles on cystine in mutant fibroblasts after 24 hour incubation, compared to the effect of 1 mM
cysteamine and in the presence of annexin V. Statistical significance is indicated by the corresponding p-value.
doi:10.1371/journal.pone.0042840.g003
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In our studies, transfection of amMSC with an expression vector
containing Red-tagged CTNS generated microvesicles richly
supplied with the tagged fusion protein. Wildtype cystinosin
contains a 39sequence which targets most of the protein to the
lysosomal membrane [1]. Nevertheless, some of this primary
isoform is also detectable at the cell surface (albeit in smaller
quantities), where it is presumably available for incorporation into
microvesicles. Furthermore, Taranta et al have reported a second
cystinosin isoform (CTNSLKG), constituting about 15% of total
cellular cystinosin, which lacks the lysosomal targeting sequence
and readily appears at the plasma membrane [18]. Since CTNS
expression is ubiquitous, it follows that any cell with an intact
CTNS gene and the capacity to shed microvesicles should be able
to reduce cystine content of adjacent mutant cells. Indeed, we
found that mutant cell cystine accumulation was reduced by co-
culture with either amMSC or genetically corrected proximal
tubular cells and by microvesicles from either amMSC or
bmMSC.
Microvesicles are known to contain proteins as well as mRNA
and miRNA [25,29]. Although, we observed microvesicle transfer
of CTNS mRNA, it is uncertain whether de novo CTNS synthesis in
Figure 4. amMSC microvesicle transfer of CTNSRed to acidic intracellular compartment of CTNS(2/2) mutant fibroblasts. (a) amMSC
stably transfected with CTNSRed immunofluorescent protein. (b) CTNSRed in amMSC microvesicles. (c) single confocal plane showing CTNSRed protein
in amMSC (circles) and in co-cultured GFP-tagged CTNS(2/2) mutant fibroblasts (arrows). Dashed line indicates amMSC cluster also shown in
brightfield insert. (d) fusion of CTNSRed particle with LysoTracker stained endosome/lysosome (arrowhead), shown in insert at higher magnification.
doi:10.1371/journal.pone.0042840.g004
Figure 5. amMSC microvesicle transfer of mRNA to CTNS(2/2)
mutant fibroblasts. (a) RT/PCR amplicon of CTNS (spanning exons 10
to 12) obtained from RNA extracted from amMSC microvesicles. (b) RT/
PCR showing absence of CTNS mRNA in GFP-tagged CTNS(2/2) mutant
fibroblasts isolated by FACS after 4 days of co-culture with untagged
mutant fibroblasts (lane 1); amplicons are evident in FACS-isolated GFP-
tagged mutant fibroblasts after 4-day co-culture with amMSC (lane 2)
and in control amMSC (lane 3).
doi:10.1371/journal.pone.0042840.g005
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the mutant cell contributes to the rescue effect. It is likely that
some cells shed more microvesicles than others and this could
influence therapeutic efficacy. Furthermore, delivery of wildtype
protein to the plasma membrane could limit the rate of protein
transfer to the mutant cells. Steinherz showed that the efflux half-
time of cystine dimethylester from heterozygous cystinotic
lysosomes is 86.3+/25 vs normal 43.1+/23 minutes [30],
suggesting that heterozygous stem cells (from a sibling or parent)
might generate less microvesicle cystinosin than a wildtype stem
cell. Although cystinosis is clinically recessive, use of heterozygous
donor cells should be carefully evaluated prior to use in clinical
trials.
A wide range of lysosomale storage diseases have been treated
with allogeneic hematopoietic stem cells derived from umbilical
cord [31]. Following myeloablative chemotherapy, engraftment is
relatively high (.90%) and serum levels of the deficient enzyme is
usually corrected. In 1968, Fratantoni reported that co-culture of
wildtype skin fibroblasts with mutant fibroblasts from patients with
alpha-L-iduronidase deficiency (Hurler syndrome) rescued the
metabolic defect [32]. The mechanism by which wildtype enzyme
was transferred to the mutant cell was unknown, but it is
conceivable that enzyme associated with microvesicle membrane
or trapped within the microvesicle is transferred in similar fashion.
On the other hand, infusion of recombinant enzyme is clinically
effective, implying that soluble enzymes may be taken up by the
mutant cell, independent of microvesicle transfer.
For years, the therapy of genetic disease has focused on: a)
vector-mediated gene transfer to mutant tissues; b) transplantation
of long-lived wildtype cells that can metabolize systemic load of
toxic metabolites; c) transplantation of stem cells that can
transdifferentiate and become integrated into mutant organs.
Our observations suggest an additional type of cell-based therapy
for genetic diseases in which microvesicle-mediated transfer of
membrane-bound proteins may correct the defect in nearby
mutant cells. This shifts the primary therapeutic consideration
toward the ability of stem cells to shed microvesicles that transfer
molecules to the mutant tissue rather than their transdifferentia-
tion potential.
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